Videos

Second-line therapies for myelofibrosis that are available or in the pipeline for use.

The panel continues their conversation about the first patient case.

Toni Choueiri, MD, introduces the first patient case: a 65-year-old man with advanced-stage renal cell carcinoma.

Alicia Morgans, MD, MPH, lists several advances being made while treating metastatic prostate cancer and offers advice to clinicians who don’t see patients with the disease very often.

An expert examines sequencing strategies for the treatment of metastatic prostate cancer.

Dr Aaron Berger shares updated safety data on next-generation androgen receptor inhibitors and impact of safety profile on treatment selection in nmCRPC.

Aaron Berger, MD, discusses adverse events with enzalutamide, apalutamide and darolutamide and their management.

Zofia Piotrowska, MD, discusses unmet needs, novel treatment strategies and future perspectives for patients with EGFR exon 20-positive NSCLC.

Zofia Piotrowska, MD, shares insights on factors to consider when selecting the appropriate therapy for patients with EGFR exon 20-positive NSCLC.

Zofia Piotrowska, MD, evaluates the use of mobocertinib in patients with NSCLC and EGFR exon 20 insertions and provides updated results from key trials of mobocertinib in EGFR exon 20-positive NSCLC.

Prostate cancer experts review the use of PSMA PET/CT imaging and Axumin imaging for patients with metastatic castration-resistant prostate cancer.

Monitoring patient response to frontline therapy for myelofibrosis, and circumstances for which a change in therapy may be appropriate.

Review of criteria used to assess and plan treatment for a 67-year-old patient with primary myelofibrosis.

Raoul S. Concepcion, MD, presents the case of a 64-year-old-man with mCRPC, and Jason M. Hafron, MD, CMO, leads the discussion on the optimal treatment approach for the given case.

Drs. Gupta and Brown review a recently published paper by Grivas et al. (2019) on the use of checkpoint inhibitors for maintenance therapy to prolong the benefits of frontline therapy while minimizing toxicity in solid tumors.

Experts discuss the use of trastuzumab-deruxtecan (T-DXd) in clinical practice.

Sara A. Hurvitz, MD, briefly describes the treatment landscape for HER2+ breast cancer and the panelists take an in-depth look at the data from the DESTINY-Breast03 trial.

In another patient case, panelists break down third-line therapy options for someone with HER2+ metastatic breast cancer and lung disease.

Moving to optimal treatment approaches in second-line therapy, experts close out a patient case of HER2+ metastatic breast cancer.

Aparna Parikh, MD, MS, discusses how her early experiences with physical fitness shaped her current relationship with exercise.

CancerNetwork® spoke with Allyson J. Ocean, MD, Diane M. Simeone, MD, Manuel Hidalgo Medina, MD, PhD, and Andrew E. Hendifar, MD, about their recent research into the treatment of pancreatic cancer.

CancerNetwork® sat down with Hossein Borghaei, DO, MS, to talk about keeping track of conference and journal updates to help build and maintain knowledge around lung cancer.

Zofia Piotrowska, MD, discusses the role of amivantamab in the treatment of patients with NSCLC and EGFR exon 20 insertions.

Zofia Piotrowska, MD, reviews historical treatment approaches for patients with NSCLC and EGFR exon 20 insertions.

Daniel P. Petrylak, MD, leads the discussion on approaching treatment of high-volume metastatic castration-naïve prostate cancer.

Considerations regarding treatment selection for patients with steroid-refractory chronic graft-vs-host disease based on current unmet needs and newer therapies in the pipeline.

Circumstances for which hydroxyurea, ruxolitinib, or other therapy may be selected to treat newly diagnosed myelofibrosis.

Reactions to a case of chronic graft-vs-host disease and thoughts on sequencing therapy.

The best practices for treating patients with steroid-refractory chronic graft-vs-host disease, with implications for using ruxolitinib based on results of the REACH3 clinical trial.

Drs Lyudmila Bazhenova and Federico Albrecht comment on the significance of real-world data collection in EGFR-mutated non–small cell lung cancer and suggest what can be done to increase the rates of real-world studies conducted.